Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of NJH395 in non‑breast HER2-positive advanced solid tumors
jRCT2080224178Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of NJH395 in Nonhematologic neoplasms and cancer, sponsored by Novartis. Primary endpoints: Maximum tolerated dose (MTD) / recommended dose (RD) and Safety and tolerability of NJH395. Started Dec 2018; status: completed.
02
Drugs
NJH395
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2080224178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224178.